A double-blind, placebo-controlled, randomised study to evaluate the safety and efficacy of a single intravenous dose of Tocilizumab for the treatment of allergen-induced asthma

Trial Profile

A double-blind, placebo-controlled, randomised study to evaluate the safety and efficacy of a single intravenous dose of Tocilizumab for the treatment of allergen-induced asthma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 24 Jun 2016

At a glance

  • Drugs Tocilizumab (Primary)
  • Indications Allergic asthma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 19 Mar 2015 Status changed from not yet recruiting to recruiting, as reported by Australian New Zealand Clinical Trials Registry.
    • 19 Mar 2014 According to Australian New Zealand Clinical Trials Registry record, anticipated date last participant will be enrolled on 1 Sep 2015.
    • 18 Mar 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top